Revenue
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kyntra Bio, Inc. (KYNB)
Price$8.55Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M | $29.6M | $46.8M | $140.7M | $235.3M | $176.3M | $256.6M | $213.0M | $131.0M | $183.2M | $180.8M | $137.6M | $102.2M |
| Gross profit | $5.9M | $14.1M | $42.8M | $120.5M | $222.4M | $167.4M | $255.4M | — | — | — | — | — | — |
| Gross margin | 91.37% | 47.47% | 91.53% | 85.59% | 94.53% | 94.97% | 99.55% | — | — | — | — | — | — |
| Research & development | $23.5M | $95.7M | $266.5M | $296.8M | $387.0M | $252.9M | $209.3M | $235.8M | $196.5M | $187.2M | $214.1M | $150.8M | $85.7M |
| Operating expenses | $52.3M | $180.0M | $369.5M | $441.8M | $523.8M | $368.2M | $345.9M | $299.7M | $248.3M | $233.2M | $258.5M | $187.7M | $110.1M |
| Operating income | −$45.9M | −$150.4M | −$322.7M | −$301.0M | −$288.5M | −$191.9M | −$89.3M | −$86.7M | −$117.3M | −$50.0M | −$77.6M | −$50.1M | −$7.9M |
| Operating margin | −712.66% | −507.80% | −689.53% | −213.90% | −122.62% | −108.83% | −34.81% | −40.71% | −89.53% | −27.32% | −42.93% | −36.41% | −7.78% |
| EBITDA | −$45.1M | −$147.7M | −$312.8M | −$290.4M | −$273.7M | −$169.8M | −$67.9M | −$80.1M | −$111.2M | −$44.0M | −$71.9M | −$45.6M | −$2.9M |
| EBITDA margin | −701.04% | −498.71% | −668.31% | −206.36% | −116.32% | −96.32% | −26.45% | −37.63% | −84.87% | −24.02% | −39.79% | −33.16% | −2.80% |
| Net income | $183.5M | −$47.6M | −$284.2M | −$293.7M | −$290.0M | −$189.3M | −$77.0M | −$86.4M | −$120.9M | −$58.1M | −$85.8M | −$59.5M | −$14.9M |
| Net profit margin | 2,848.63% | −160.63% | −607.29% | −208.66% | −123.25% | −107.36% | −30.00% | −40.58% | −92.27% | −31.70% | −47.44% | −43.24% | −14.63% |
| Basic EPSper basic share | $45.37 | -$11.89 | -$73.00 | -$78.50 | -$78.50 | -$52.75 | -$22.25 | -$25.75 | -$41.50 | -$23.25 | -$35.50 | -$79.25 | -$28.25 |
| Diluted EPSper diluted share | $45.37 | -$11.89 | -$73.00 | -$78.50 | -$78.50 | -$52.75 | -$22.25 | -$25.75 | -$41.50 | -$23.25 | -$35.50 | -$79.25 | -$28.25 |
Owners
Reported shareholders
9.88%of listed shares
ARMISTICE CAPITAL, LLC400K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
ARMISTICE CAPITAL, LLC | 9.88%400K shares |
Chung Christine | ≈7.28%294.9K shares |
Graham Juan | ≈4.07%164.86K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.95%159.95K shares |
ACADIAN ASSET MANAGEMENT LLC | 2.61%105.59K shares |
BlackRock, Inc. | 2.08%84.33K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.07%43.22K shares |
HighTower Advisors, LLC | 0.98%39.75K shares |
Schoeneck James A | —39.67K shares |
TWO SIGMA INVESTMENTS, LP | 0.98%39.51K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.67%27.08K shares |
Wettig Thane | ≈0.67%27.05K shares |
VANGUARD FIDUCIARY TRUST CO | 0.60%24.11K shares |
Birchview Capital, LP | 0.56%22.57K shares |
STATE STREET CORP | 0.50%20.28K shares |
GSA CAPITAL PARTNERS LLP | 0.39%15.7K shares |
UBS Group AG | 0.19%7.86K shares |
GROUP ONE TRADING LLC | 0.11%4.41K shares |
DeLucia David | ≈0.11%4.38K shares |
Vanguard Global Advisers, LLC | 0.04%1.42K shares |
Percentages use 4.05M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 14, 2026Form 4/A | Wettig ThaneCEO | BuyCommon Stock | 2.8K | $7.09 | $19.9K | 27.2K |
| May 14, 2026Form 4 | Wettig ThaneCEO | BuyCommon Stock | 2.8K | $7.09 | $19.9K | 27.2K |
| Nov 17, 2025Form 4 | Wettig ThaneCEO | BuyCommon Stock | 2.7K | $9.10 | $24.6K | 24.9K |
| Nov 13, 2025Form 4 | Wettig ThaneCEO | BuyCommon Stock | 1.0K | $9.18 | $9.2K | 22.2K |
| Jun 30, 2025Form 4 | Schoeneck James ADirector | BuyCommon Stock · indirect | 23.6K | $5.07 | $119.5K | 39.7K |